WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Zahlen folgen am 23.03.

Nach dem starken Anstieg der letzten Monate wird nun heftig korrigiert. Credit Suisse begründet dazu die aktuelle Lage und benennt ein Kursziel im folgenden Link (ein Fall für den Übersetzer): http://www.aastocks.com/tc/stocks/news/aafn-con/rum.210308_101720/latest-news

Bin durch Zufall auf diese Aktie gestoßen. Hört sich alles sehr interessant an! Weiß jemand wie hoch das Kursziel hier ist?

Oh man oh man, mit sowas hab ich hier nun wirklich nicht gerechnet... Werde bei 7,5 € wohl noch mal stark nachlegen. Hoffe aber innerlich, dass wir den Bereich nicht sehen werden.

Bin gespannt wo die Reise hingeht.

Aktuell nicht mehr ganz so tief im Minus, wie zum Zeitpunkt des Schreibens. WuXi Biologics (02269) fell more than 6% and temporarily led the decline. Blue chips were recently reduced by Xiaomo and involved HK$322 million https://m.jrj.com.cn/madapter/hk/2021/03/05093632076584.shtml Zhitong Finance APP learned that according to the equity information of the Hong Kong Stock Exchange, on March 1, WuXi Biologics (02269) was reduced by JPMorgan Chase's holdings of 3,168,900 shares, with an average price of 101.5446 Hong Kong dollars per share and approximately 322 million Hong Kong dollars in capital. WuXi Biologics fell more than 6% in intraday trading, temporarily leading the blue-chip decline. As of press time, it fell 5.43% to HK$87, with a turnover of HK$589 million.

Credit Suisse: WuXi Biologics (02269 HK) Affected by Vir's Phase III Failure of New Coronary Neutralizing Antibody Research and Development May Make Share Price Fluctuate http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1080351/1 ... The bank said that Vir’s recent development of the new crown neutralizing antibody (VIR-7831) failed in Phase III clinical trials, and the company has a research agreement with Vir. The news may bring fluctuations in WuXi Biologics stock price, but the bank is expected to have limited impact on the company’s actual income ; Similarly, the recent failure of Amicus to develop AT-GAA (potentially the third phase of WuXi Biologics), drugs involving late-onset Pompe disease should also not have a significant impact on the company's revenue potential. ...

Hang Seng, China shares sink https://www.thestandard.com.hk/breaking-news/section/2/166698/Hang-Seng,-China-shares-sink

C Suisse: WUXI BIO (02269 HK) Shr Price Likely Bumpy on Vir COVID Neutrializing Antibody Clinical Trial Failure http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1080338/hk-stock-news

Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility https://www.prnewswire.co.uk/news-releases/remote-pre-approval-inspection-completed-by-ema-on-wuxi-biologics-mfg4-facility-895797546.html

Eher allgemein und etwas länger. WuXi findet im unteren Drittel auch seine Erwähnung: China: Ein hoffnungsvoller Markt für Gesundheitsinnovationen https://e-fundresearch.com/newscenter/199-pgim-investments/artikel/40498-china-ein-hoffnungsvoller-markt-fuer-gesundheitsinnovationen

https://finance.sina.cn/hkstock/ggpj/2021-03-03/detail-ikftssaq0070680.d.html?from=wap Die Bank of Communications International veröffentlichte einen Bericht, wonach die neue Version des Krankenversicherungskatalogs ab dem 1. März vollständig implementiert sein wird. Es sind 119 neue Medikamente und 16 neu gelistete Medikamente enthalten. Die durchschnittliche Preissenkung für erfolgreich verhandelte Medikamente beträgt 50,64% . Die Aufnahme neu vermarkteter Arzneimittel in den Krankenversicherungskatalog setzt Signale für die Anerkennung und Unterstützung innovativer Arzneimittel und verbessert den Zugang der Patienten zu innovativen Arzneimitteln. Davon profitieren führende Pharmaunternehmen und CXO-Unternehmen, darunter China Biopharmaceuticals (01177-HK / Kauf) und WuXi Biologics (02269-HK / Kauf).

📍

DATE OF BOARD MEETING Download https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a210226.pdf

WuXi Biologics (02269.HK) issued an announcement that the company would like to hold a board meeting on March 23, 2021 (Tuesday), in order to (including) consider and approve the group as of December 2020 Annual results and publication for the year ended on the 31st. https://m.jrj.com.cn/madapter/hk/2021/02/26163232033312.shtml

Hong Kong stocks slump with global sell-off as taper tantrum triggers bond market rout, mainland funds trim bets again https://amp.scmp.com/business/markets/article/3123202/hong-kong-stocks-plunge-global-sell-taper-tantrum-triggers-bond • Stocks crash across the region as traders begin to price in interest-rate increase amid policy tightening risks, inflation concerns • WuXi Biologics, Galaxy Entertainment and Meituan lead slump, mainland investors turn net sellers of Hong Kong stocks again Hong Kong stocks tumbled, joining a global rout, after a sell-off in US government bonds amid concerns central banks will unwind accommodative monetary policies that have fed an unprecedented rally in global equities. The Hang Seng Index sank 2.4 per cent to 29,342.49 at local noon break as 50 of the 52 members suffered losses. WuXi Biologics, Macau casino operator Galaxy Entertainment and Meituan retreated at least 5.8 per cent as the worst performers. ... WuXi Biologics fell 7.8 per cent to HK$96.20, the lowest since January 8. Galaxy dropped for a third day, losing 6.5 per cent to HK$69.25. Meituan 5.8 per cent to HK$349, the lowest since January 19. ...